Target intelligence / Profile preview

CD3, CD4, CD8 antigens (CD3, CD4, CD8)

Target
CD3, CD4, CD8
Molecular classification
Receptor complex (signal transduction adaptor), immune cell marker, Immunoglobulin superfamily, Co-receptor
01

Overview

CD3, CD4, and CD8 are critical surface antigens present on different subsets of human T lymphocytes. CD3 antigen is a multisubunit protein complex associated with the T cell receptor (TCR), serving as a key signal transduction adaptor. It is used as a pan-T cell marker and is essential for T cell activation. CD4 antigen acts as a co-receptor on helper T cells, binding to MHC class II molecules and facilitating immune coordination and activation; it is a primary target for HIV entry. CD8 antigen serves as a co-receptor on cytotoxic T cells, binding MHC class I molecules and enabling recognition/killing of infected and cancerous cells. All three are leveraged as diagnostic markers and therapeutic targets in immuno-oncology, infectious diseases, and immune modulation, but should be treated as separate, distinct targets for structural annotation and drug development.

Other names
T3 complexCluster of Differentiation 3Helper T cell markerCluster of Differentiation 4Cytotoxic T cell markerCluster of Differentiation 8
02

Mechanism of action

Targeting these antigens involves modulation or depletion of T cells, induction of signaling, immunosuppression, inhibition of HIV entry, or enhancement of T cell-mediated cytotoxicity to influence immune responses.

03

Biological functions

Signal transductionT cell activationimmune responsecell differentiationHelper T cell differentiationMHC class II recognitionimmune response coordinationCytotoxic T cell differentiationMHC class I recognitionelimination of infected/cancerous cells
04

Disease associations

Cancer (T cell lymphomas/leukemias, tumor immunotherapy)Autoimmune disease (T cell-mediated autoimmunity, e.g. type I diabetes, multiple sclerosis)Infection (HIV targets CD4; viral/cellular immunity)Inflammation (tissue damage, immune dysregulation)
05

Safety considerations

Cytokine release syndrome (esp. CD3-targeting drugs)Immunosuppression with increased infection riskAutoimmunityOff-target depletion of T cell subsetsHIV entry facilitation via CD4
06

Interacting drugs

Anti-CD3 antibodies (e.g., OKT3/muromonab)

5 more in the full profile.

07

Biomarkers

Marker for total T cell count (diagnostic in lymphoma/leukemia)efficacy monitoring in immunotherapyMarker for helper T cellsused in HIV/AIDS monitoring (CD4 count)Marker for cytotoxic T cellsused to assess immune status, cancer immunotherapy responses

Beyond the preview

Go deeper on CD3, CD4, CD8 antigens (CD3, CD4, CD8).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CD3, CD4, CD8 antigens (CD3, CD4, CD8).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call